Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.

ABSTRACT: Estrogen receptor-positive and human epidermal growth factor receptor 2-negative (ER⁺ HER2^- ) breast cancer accounts for ~ 60-70% of all cases of invasive breast carcinoma. High-grade ER⁺ HER2^- tumors respond poorly to endocrine therapy. In this study, we systematically analyzed clinical and multi-omics data to find potential strategies for personalized therapy of patients with high-grade ER⁺ HER2^- disease. Six different cohorts were analyzed, for which multi-omics data were available. Grade III ER⁺ HER2^- cases harbored higher proportions of large tumor size (> 5 cm), lymph node metastasis, chemotherapy use, and luminal B subtypes defined by PAM50, as compared with grade I/II tumors. DNA methylation (HM

SUBMITTER: Wang K 

PROVIDER: S-EPMC9208078 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature